Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Spain · Delayed Price · Currency is EUR 53.75
+0.65 (1.22%)
Aug 8, 2025, 5:35 PM CET
Oncternal Therapeutics Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 132.27 | 136.88 | 170.34 | 199.67 | 153.08 | 61.06 | Upgrade |
Depreciation & Amortization | 28.01 | 26.92 | 23.44 | 21.84 | 20.3 | 18.31 | Upgrade |
Other Amortization | 1.31 | 1.09 | 0.9 | 1.03 | 1.06 | 1.29 | Upgrade |
Loss (Gain) From Sale of Assets | 4.39 | 4.39 | - | - | - | - | Upgrade |
Loss (Gain) From Sale of Investments | 0.46 | -0.08 | 0.22 | -1.83 | -1.16 | 0.25 | Upgrade |
Loss (Gain) on Equity Investments | 0.19 | 0.14 | 0.13 | -0.2 | -0.18 | 0.03 | Upgrade |
Stock-Based Compensation | - | - | - | - | 1.4 | - | Upgrade |
Provision & Write-off of Bad Debts | -7.97 | -7.97 | -0.04 | 0.04 | -0.27 | -0.24 | Upgrade |
Other Operating Activities | -37.87 | -32.06 | -47.28 | 74.03 | 39.24 | 29.94 | Upgrade |
Change in Accounts Receivable | -4.99 | 13.41 | 19.47 | -26.82 | -74.19 | 7.47 | Upgrade |
Change in Inventory | 34.25 | 11.87 | -29.29 | -71.59 | -23.43 | -70.4 | Upgrade |
Change in Accounts Payable | -12.92 | -16.36 | -23.92 | 41.67 | 35.36 | -0.81 | Upgrade |
Change in Other Net Operating Assets | -0.57 | 0.04 | -0.7 | -0.23 | -1.78 | -0.01 | Upgrade |
Operating Cash Flow | 136.55 | 138.28 | 113.25 | 237.6 | 149.44 | 46.88 | Upgrade |
Operating Cash Flow Growth | 50.96% | 22.10% | -52.34% | 58.99% | 218.80% | - | Upgrade |
Capital Expenditures | -61.25 | -59.12 | -53.79 | -50.72 | -40.22 | -39.34 | Upgrade |
Sale of Property, Plant & Equipment | 0.11 | 0.04 | 0.38 | 0.08 | 0.03 | 0.06 | Upgrade |
Sale (Purchase) of Intangibles | -3.13 | -3.1 | -1.39 | -0.67 | -0.72 | -0.36 | Upgrade |
Investment in Securities | -22.3 | -19.01 | 1.29 | -5.85 | - | - | Upgrade |
Other Investing Activities | 0.28 | 0.13 | 1.49 | 0.01 | 0.07 | 0 | Upgrade |
Investing Cash Flow | -86.3 | -81.06 | -52.03 | -57.15 | -40.84 | -39.63 | Upgrade |
Long-Term Debt Issued | - | 96.95 | 0.73 | 1.4 | 1.34 | 1.43 | Upgrade |
Long-Term Debt Repaid | - | -51.71 | -13.65 | -6.77 | -6.19 | -13.18 | Upgrade |
Net Debt Issued (Repaid) | 5.18 | 45.24 | -12.92 | -5.37 | -4.85 | -11.75 | Upgrade |
Issuance of Common Stock | 69.2 | 41.92 | 52.64 | 77.77 | 42.33 | 37.49 | Upgrade |
Repurchase of Common Stock | -65.98 | -89.71 | -133.9 | -177.01 | -78.79 | -37.26 | Upgrade |
Common Dividends Paid | -56.45 | -56.45 | -69.05 | -51.01 | -21.13 | -9.7 | Upgrade |
Other Financing Activities | -2.73 | 3.64 | 2.39 | 1.08 | -0.29 | -0.3 | Upgrade |
Financing Cash Flow | -50.78 | -55.36 | -160.84 | -154.54 | -62.73 | -21.52 | Upgrade |
Net Cash Flow | 1.54 | 1.86 | -99.62 | 25.91 | 45.87 | -14.26 | Upgrade |
Free Cash Flow | 75.3 | 79.16 | 59.45 | 186.88 | 109.22 | 7.54 | Upgrade |
Free Cash Flow Growth | 105.54% | 33.15% | -68.19% | 71.10% | 1348.77% | - | Upgrade |
Free Cash Flow Margin | 10.05% | 10.37% | 7.17% | 22.86% | 16.84% | 1.80% | Upgrade |
Free Cash Flow Per Share | 1.47 | 1.55 | 1.12 | 3.50 | 1.97 | 0.14 | Upgrade |
Cash Interest Paid | 2.56 | 1.77 | 0.39 | 0.29 | 0.29 | 0.45 | Upgrade |
Cash Income Tax Paid | 45.7 | 44.23 | 40.86 | 43.89 | 23.86 | 6.04 | Upgrade |
Levered Free Cash Flow | 7.13 | 44.63 | 25.36 | 135.92 | 66.2 | -12.05 | Upgrade |
Unlevered Free Cash Flow | 9.03 | 46.09 | 25.95 | 136.45 | 66.76 | -11.38 | Upgrade |
Change in Net Working Capital | 63.82 | 31.39 | 80.36 | -6.38 | 28.78 | 38.11 | Upgrade |
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.